# Imugene

Source: https://onco.cc/companies/imugene/  
OnCo record `imugene` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Imugene is an Australian company now focused on an off-the-shelf CAR-T cell therapy made from donor cells for people with blood cancers that have come back after other treatments.

## Summary

Imugene Limited, headquartered in Sydney and listed on the ASX, describes itself as a clinical-stage cell therapy company developing off-the-shelf cancer treatments. Its lead programme azer-cel (azercabtagene zapreleucel) is an allogeneic CD19-directed CAR-T therapy in a phase 1/1b open-label study in relapsed or refractory non-Hodgkin lymphoma and B cell acute lymphoblastic leukaemia, recruiting in Australia and the United States. The company previously developed oncolytic virus (VAXINIA / CF33, onCARlytics) and B cell vaccine (HER-Vaxx, PD1-Vaxx) programmes, but these are not described on the current website, which centres on azer-cel. No capital raising could be sourced from fetched pages.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Sydney
- Type: cell-therapy
- Website: https://www.imugene.com

## Notes

- ASX code IMU (IMU.AX) not confirmed on fetched pages, so ticker omitted. Oncolytic virus and vaccine programmes not visible on the current site; companyType set to cell-therapy to match the current lead. dlbcl used as the closest id for relapsed or refractory non-Hodgkin lymphoma.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Imugene
- Official website: https://www.imugene.com
- Clinical trials: https://imugene.com/pipeline/clinical-trials/

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)

---
JSON: https://onco.cc/api/v1/entities/imugene.json